Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
- 18 August 2010
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 335 (2), 266-272
- https://doi.org/10.1124/jpet.110.168385
Abstract
Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In the past several years, the role of HDACs in cancer initiation and progression, as well as the therapeutic effects of HDAC inhibitors in various types of cancer, has been well studied. Recent studies indicated that HDAC activity is also associated with the development and progression of some chronic diseases characterized by fibrosis, including chronic kidney disease, cardiac hypertrophy, and idiopathic pulmonary fibrosis. Here, we review what is known about HDACs in the progression of tissue fibrosis and the potential applications of HDAC inhibitors in the treatment of disorders associated with fibroblast activation and proliferation.This publication has 80 references indexed in Scilit:
- Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD modelsProceedings of the National Academy of Sciences of the United States of America, 2009
- Abrogation of TGF-β1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibitionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Defective Histone Acetylation Is Responsible for the Diminished Expression of Cyclooxygenase 2 in Idiopathic Pulmonary FibrosisMolecular and Cellular Biology, 2009
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensinJournal of Molecular and Cellular Cardiology, 2008
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- The epigenetic signature of CFTR expression is co-ordinated via chromatin acetylation through a complex intronic elementBiochemical Journal, 2007
- HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary CiliumCell, 2007
- Histone deacetylase inhibitors for epigenetic therapy of cancerAnti-Cancer Drugs, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007